PurposeExpresses the human MAVS CDS containing a point mutation M1A and a C-terminal deletion removing the transmembrane domain
Full plasmid sequence is not available for this item.
|Item||Catalog #||Description||Quantity||Price (USD)|
|Plasmid||52003||Standard format: Plasmid sent in bacteria as agar stab||1||$85|
This material is available to academics and nonprofits only.
Vector typeMammalian Expression
Growth in Bacteria
Bacterial Resistance(s)Ampicillin, 100 μg/mL
Copy numberHigh Copy
Mutationchanged Met 1 to Ala and deleted the C-terminal transmembrane domain
- Cloning method Restriction Enzyme
- 5′ cloning site unknown (unknown if destroyed)
- 3′ cloning site unknown (unknown if destroyed)
- 5′ sequencing primer CMV-F
- 3′ sequencing primer BGH-Rev (Common Sequencing Primers)
Terms and Licenses
- Not Available to Industry
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
For your Materials & Methods section:pcDNA3-MAVS-M1A500(KaganF60) was a gift from Jonathan Kagan (Addgene plasmid # 52003 ; http://n2t.net/addgene:52003 ; RRID:Addgene_52003)
For your References section:A Bicistronic MAVS Transcript Highlights a Class of Truncated Variants in Antiviral Immunity. Brubaker SW, Gauthier AE, Mills EW, Ingolia NT, Kagan JC. Cell. 2014 Feb 13;156(4):800-11. doi: 10.1016/j.cell.2014.01.021. 10.1016/j.cell.2014.01.021 PubMed 24529381